Short answer
Aquestive Therapeutics, Inc. (AQST) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation disclosed at the Jefferies Global Healthcare Conference on November 16, 2026.
Aquestive Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation disclosed at the Jefferies Global Healthcare Conference on November 16, 2026
- Presentation provides management’s latest investor messaging and may influence analyst expectations
- Exhibit 99.1 contains the substantive presentation materials for review
Item EX-99.1 · Exhibit EX-99.1
- Anaphylm NDA resubmission accepted, with FDA PDUFA goal date March 16, 2027, creating a major near-term regulatory catalyst
- Cash and equivalents $90.3 million at September 30, 2026, with potential access to $75 million RTW funding and $20 million Oaktree debt
- Planned U.S. launch contingent on approval, targeting approximately 75 sales representatives and approximately 8,000 priority healthcare providers
- Canada filing targeted by year-end 2026 and European Union filing in Q1 2027, with ex-U.S. licensing rights available
- Pipeline opportunity exceeds $1.5 billion in potential peak annual net sales, including Anaphylm, Libervant and AQST-108 estimates
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aquestive Therapeutics, Inc. 8-K filings
Get the next AQST 8-K as it lands
Follow AQST for push alerts, or ask the research agent what this filing means.